SCHEMBL706155

SCHEMBL706155

CC(c1ccccc1)N1CC2(C)CCCN2C1=O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.43
CYP2D6 P10635 5/20 0.40
OPRM1 P35372 3/20 0.39
OPRD1 P41143 3/20 0.39
OPRK1 P41145 3/20 0.39
OPRL1 P41146 3/20 0.39
KMT2A Q03164 1/20 0.38
MC4R P32245 1/20 0.36
CYP3A4 P08684 4/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 3/20 0.34
USP2 O75604 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP1A2 P05177 2/20 0.34
MAPK1 P28482 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL705521 0.86 HSD11B1 (0.46) HSD11B1OPRM1KMT2A
SCHEMBL703315 0.85 MET (0.36) OPRM1OPRD1OPRK1OPRL1KMT2A
SCHEMBL703100 0.82 HSD11B1 (0.47) HSD11B1OPRM1OPRD1OPRK1OPRL1
SCHEMBL706528 0.75 HSD11B1 (0.47) HSD11B1KMT2AMC4RCYP3A4CYP2C9
SCHEMBL702945 0.70 KMT2A (0.52) CYP2D6OPRM1OPRL1KMT2ACYP3A4
SCHEMBL4793751 0.68 HSD11B1 (0.41) HSD11B1CYP2D6OPRM1OPRD1OPRK1
SCHEMBL10306123 0.67 KMT2A (0.47) HSD11B1CYP2D6OPRM1OPRD1OPRK1
SCHEMBL14177736 0.67 MMP1 (0.63) HSD11B1CYP2D6OPRM1OPRD1OPRK1
SCHEMBL14177737 0.67 MMP1 (0.63) HSD11B1CYP2D6OPRM1OPRD1OPRK1
SCHEMBL4795085 0.67 HSD11B1 (0.43) HSD11B1CYP2D6OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280970-B1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2014-01-08 EP claimed
US-8124636-B2 Imidazolidinone derivatives as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US claimed
US-20090275573-A1 Imidazolidinone Derivatives as 11B-HSD1 Inhibitors HOFFMANN-LA ROCHE, INC. 2009-11-05 US claimed
EP-2280970-B1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
US-8124636-B2 Imidazolidinone derivatives as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US disclosed
EP-2280970-A1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-02-09 EP disclosed
WO-2009132986-A1 IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-11-05 WO disclosed
US-20090275573-A1 Imidazolidinone Derivatives as 11B-HSD1 Inhibitors HOFFMANN-LA ROCHE, INC. 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275573-A1 Imidazolidinone Derivatives as 11B-HSD1 Inhibitors HSD11B1, HSD17B1, HSD17B11 HSD11B1 1/4885CYP2D6 125/4885OPRM1 3760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.